uniQure (QURE) to Release Quarterly Earnings on Tuesday

uniQure (NASDAQ:QURE - Get Free Report) is projected to post its Q2 2025 quarterly earnings results before the market opens on Tuesday, July 29th. Analysts expect uniQure to post earnings of ($0.89) per share and revenue of $5.00 million for the quarter.

uniQure (NASDAQ:QURE - Get Free Report) last posted its earnings results on Friday, May 9th. The biotechnology company reported ($0.82) EPS for the quarter, topping the consensus estimate of ($1.07) by $0.25. uniQure had a negative net margin of 1,077.05% and a negative return on equity of 483.87%. The firm had revenue of $1.57 million for the quarter, compared to analysts' expectations of $5.93 million. On average, analysts expect uniQure to post $-4 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

uniQure Stock Performance

Shares of uniQure stock traded down $0.10 during mid-day trading on Friday, hitting $15.11. 593,394 shares of the stock were exchanged, compared to its average volume of 1,010,815. uniQure has a 12 month low of $4.45 and a 12 month high of $19.18. The company has a 50-day simple moving average of $14.94 and a 200 day simple moving average of $13.70. The company has a debt-to-equity ratio of 1.53, a quick ratio of 11.99 and a current ratio of 11.99. The company has a market capitalization of $827.73 million, a P/E ratio of -3.44 and a beta of 0.08.

Insider Buying and Selling

In related news, insider Jeannette Potts sold 4,670 shares of the company's stock in a transaction that occurred on Monday, June 16th. The stock was sold at an average price of $15.14, for a total value of $70,703.80. Following the transaction, the insider directly owned 115,073 shares of the company's stock, valued at approximately $1,742,205.22. This represents a 3.90% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Rachelle Suzanne Jacques sold 2,112 shares of the stock in a transaction on Friday, June 20th. The shares were sold at an average price of $14.45, for a total value of $30,518.40. Following the transaction, the director directly owned 28,346 shares in the company, valued at $409,599.70. The trade was a 6.93% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 22,144 shares of company stock worth $322,426 over the last 90 days. 4.79% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On uniQure

An institutional investor recently raised its position in uniQure stock. Woodline Partners LP boosted its holdings in uniQure N.V. (NASDAQ:QURE - Free Report) by 25.0% in the first quarter, according to its most recent filing with the SEC. The institutional investor owned 175,806 shares of the biotechnology company's stock after buying an additional 35,175 shares during the period. Woodline Partners LP owned 0.32% of uniQure worth $1,864,000 as of its most recent SEC filing. 78.83% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on QURE. Chardan Capital restated a "buy" rating and set a $38.00 price target on shares of uniQure in a research note on Friday, May 30th. HC Wainwright restated a "buy" rating and set a $70.00 price target on shares of uniQure in a research report on Thursday, May 29th. Cantor Fitzgerald raised shares of uniQure to a "strong-buy" rating in a report on Monday, May 19th. Wall Street Zen downgraded shares of uniQure from a "hold" rating to a "sell" rating in a research note on Saturday, June 14th. Finally, Guggenheim reaffirmed a "buy" rating and set a $28.00 price objective on shares of uniQure in a research note on Monday, May 12th. One investment analyst has rated the stock with a sell rating, three have given a hold rating, six have given a buy rating and two have given a strong buy rating to the company. According to MarketBeat.com, uniQure presently has an average rating of "Moderate Buy" and a consensus target price of $37.82.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.